{"id":"carperitide-heart-failure-therapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Worsening renal function"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Carperitide mimics the natural hormone ANP, which activates guanylate cyclase-coupled natriuretic peptide receptors on vascular smooth muscle and cardiac tissue. This activation increases intracellular cGMP, leading to vasodilation, reduced sympathetic nervous system activity, decreased aldosterone secretion, and improved renal sodium and water excretion. These effects collectively reduce cardiac workload and improve hemodynamics in acute decompensated heart failure.","oneSentence":"Carperitide is a recombinant human atrial natriuretic peptide (ANP) that binds to natriuretic peptide receptors to promote vasodilation, reduce cardiac preload and afterload, and improve cardiac output in heart failure.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:29:48.928Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute decompensated heart failure"}]},"trialDetails":[{"nctId":"NCT00259038","phase":"PHASE2","title":"Evaluation of the Effects of Carperitide in Patients With Congestive Heart Failure","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2004-01","conditions":"Heart Failure, Congestive, Heart Decompensation, Left Ventricular Failure","enrollment":162},{"nctId":"NCT00613964","phase":"PHASE4","title":"The Effects of Carperitide on Short and Long-term Prognosis in Patients With Both Cardiac and Renal Failure","status":"TERMINATED","sponsor":"Nara Medical University","startDate":"2009-05","conditions":"Heart Failure, Renal Failure","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Loop-diuretics etc + HANP"],"phase":"marketed","status":"active","brandName":"Carperitide heart failure therapy","genericName":"Carperitide heart failure therapy","companyName":"Nara Medical University","companyId":"nara-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Carperitide is a recombinant human atrial natriuretic peptide (ANP) that binds to natriuretic peptide receptors to promote vasodilation, reduce cardiac preload and afterload, and improve cardiac output in heart failure. Used for Acute decompensated heart failure.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}